OXB’s strategy is underpinned by its LentiVector technology. It generates significant revenue from a multitude of partners that use its technology and is manufacturing the COVID-19 vaccine Vaxzevria (AZD1222) for AstraZeneca. OXB is implementing significant capacity upgrades to enable more partnering/out-licensing agreements.
More Oxford Biomedica content >Investment summary
Oxford Biomedica (OXB) is a global leader in lentiviral development and manufacturing. It is expanding its manufacturing facilities through Oxbox, a 84,000 sq ft state-of-the-art bioprocessing facility, significantly increasing its production capacity to match increasing demand and to continue growing its platform revenues. In the near term, revenues will continue to be driven by Novartis and AstraZeneca as rollout of Kymriah and the COVID-19 vaccine continues, as well as new partner programmes such as those from Bristol Myers Squibb (BMS). OXB has several established development and manufacturing partnerships including Novartis, Juno Therapeutics (BMS), Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, Santen, Beam Therapeutics and PhoreMost. OXB also has a supply agreement with AstraZeneca for the large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine Vaxzevria (AZD1222). Our forecasts are under review.
Y/E Dec |
Revenue (£m) |
EBITDA (£m) |
PBT (£m) |
EPS (p) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2019A | 64.1 | (4.6) | (16.8) | (16.4) | N/A | 198.6 |
| 2020A | 87.7 | 8.3 | (2.5) | (2.7) | N/A | 48.4 |
| 2021E | 159.1 | 28.6 | 18.6 | 20.3 | 47.1 | N/A |
| 2022E | 173.4 | 39.2 | 28.0 | 30.6 | 31.2 | 245.1 |
Industry outlook
Cell and gene therapy is the focus of much industry attention as it can dramatically alter the outcomes of many diseases. OXB’s proprietary LentiVector platform has demonstrated promise in many indications.
Last updated on 20/01/2022Content on Oxford Biomedica
Sector |
|---|
|
Healthcare
Access more Healthcare content
|
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (£m) | 16.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| John Dawson | CEO |
| Stuart Paynter | CFO |